Marker Therapeutics, Inc. (MRKR)
Last updated: 2026-10-28 11:47:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Summary
Marker Therapeutics, Inc. (MRKR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.95, with a market capitalization of $15.11M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.84 to $2.46. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$15.11M | |
$0.95 | |
$102.50 | |
$0.67 | |
$0.95 | |
340.00 | |
108.70K | |
-- | |
$2.46 | |
$0.84 | |
-- | |
-- |
Marker Therapeutics, Inc. (MRKR) Pre-Market Stock Price
Marker Therapeutics, Inc. (MRKR) is trading at $0.95 in pre-market trading as of 2026-10-28 11:37:00, down 0.35% ($0.00) from the previous close of $0.95
Pre-market trading shows how investors are pricing MRKR before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Marker Therapeutics, Inc. (MRKR) 7-Day Stock Price Change
Over the past seven days, Marker Therapeutics, Inc. (MRKR) moved from $1.20 to $0.95, representing a decline of 21.00% ($0.25).
The stock traded between $0.87 and $1.27 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 209.91 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
MRKR 52-Week Price Position
Position in Range: 6.7%
MRKR is currently trading at $0.95, placing it 6.7% of the way from its 52-week low of $0.84 to its 52-week high of $2.46. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Marker Therapeutics, Inc. (MRKR)?
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Marker Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 5 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Marker Therapeutics, Inc. (MRKR) Stock on MEXC
Eligible investors can buy real shares of Marker Therapeutics, Inc. (MRKR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Marker Therapeutics, Inc. (MRKR) stock price today?
2.Is MRKR stock going up or down today?
3.What is MRKR pre-market price?
4.What is MRKR after-hours price?
5.Is MRKR stock trading now?
6.Where does MRKR sit relative to its 52-week high and low?
7.What sector is Marker Therapeutics, Inc. in?
8.What is Marker Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is MRKR valued in terms of P/E ratio and EPS?
10.Does Marker Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
MRKR Stock Calculator
Estimate the value between MRKR shares and USD.
MRKR Shares to USD
1.00 MRKR shares = 0.948 USD
Calculations are estimates based on the latest available price and are for reference only.


